Pierre Blanchard, MD
@PBlanchardMD
Followers
5K
Following
6K
Media
689
Statuses
4K
Full Prof Radiation Oncology @gustaveroussy @UnivParisSaclay. EiC https://t.co/EihrJjVxi0. Director @SciencesCancer. Adjunct Prof @MDAndersonNews.
Villejuif, France
Joined May 2015
It's official! 🍾 I have been appointed Editor in Chief of Radiotherapy & Oncology, aka the Green Journal, @ESTRO_RT's first official journal, starting May 2024. Extremely honored, but also a bit frightened by the task. Big shoes to fill. Will do one step at a time...
89
25
526
Ever wondered which patients get GU adverse events after prostate SBRT? Some pointers here https://t.co/dQcqRXTN4O
5
27
63
Notre application @GustaveRoussy fait peau neuve ! Consultez le site ou téléchargez l’app. Déjà téléchargée plus de 20.000 fois, l’appli couvre tous les domaines de l’oncologie, et sera utile à tous publics, médecin, interne, soignant ou simple curieux ! Liens en bas du fil
📱 Le manuel pratique d'oncologie de @GustaveRoussy est une application initialement destinée aux internes et utilisée par un public toujours plus large : médecins en exercice, personnels paramédicaux...
0
6
10
Digital oncology is here to stay. Randomized trial of smartphone assisted follow up shows it prevents deterioration of quality of life in head and neck cancer survivors. Stefano Cavalieri at #ESMO25
1
21
38
Say hello to a different way of printing denim. Our Cool Transfer Printing tech lets us create vibrant, on-trend prints with less water. Next-gen denim is here. Ready to experience the future of fashion? Click the link to learn more about this innovative process.
9
38
265
🚨improved OS with ADT+enza in high risk BCR (biochemical recurrent) #prostatecancer New standard of care but important to reconcile the data with the results of PRESTO AFT19 (apalutamide) & integration in current landscape (PSMA, MDT). #ESMO25
1
31
65
PRESTO at #ESMO25 No MFS benefit of the addition of apalutamide to ADT in high risk biochemically recurrent #prostatecancer Conflicting results with EMBARK: Differences in populations? MFS definition (PSMA allowed in PRESTO)? Better local threat in PRESTO?
2
33
61
🚨ENZARAD at #ESMO25 presented by @DrPaulNguyen No improvement in MFS or OS with the addition of enzalutamide to high dose radiotherapy + 2y ADT in high risk #prostatecancer Possible benefit in cN1 pts or pts treated with pelvic RT.
3
43
86
Key question is whether this would allow bladder preservation protocols and not cystectomy. What is the point of removing 57% of intact bladders? Could we do less to improve patients QoL? #radonc
KN905 Very impressive results with neoadjuvant EV-P in cisplatin-ineligible muscle invasive #bladdercancer presented by C Vulsteke at #ESMO25 ✅Improved PFS & OS ✅High path CR rates (57%) ✅No delay in surgery ✅Expected toxicity in this frail population New SOC
8
30
95
LIMITED-TIME OFFER! Did you miss out on our in-person collaborations? Don’t worry — we’re at it again! Starting 10/25, grab your ax chibi 3-Day wristband for just $25 at the select locations below!
0
0
5
KN905 Very impressive results with neoadjuvant EV-P in cisplatin-ineligible muscle invasive #bladdercancer presented by C Vulsteke at #ESMO25 ✅Improved PFS & OS ✅High path CR rates (57%) ✅No delay in surgery ✅Expected toxicity in this frail population New SOC
3
19
49
Huge effort by @DrGopalIyer and team in evaluating nimotuzumab (EGFR inhibitor Ab) to adjuvant chemoRT in resected head and neck cancer. Trial negative overall. possible impact in oral cavity,’ (p16neg) where EGFR inhib works best. Consistent with our meta analysis. #ESMO26
1
8
16
🚨Important update from ProtecT #ProstateCancer trial after central pathology review 1️⃣ Which early PCa need treatment? Which do not? 2️⃣ For “bad” early PCa, do RP or RT prevent long-term (15y) metastasis? 🧵1/ @OncoAlert @urotoday @PCF_Science @JAMAOnc @Uroweb @AmerUrological
1/2 Just published in @JAMAOnc: 15-year outcomes of Active Monitoring, Surgery, and Radiotherapy for cribriform-positive and cribriform-negative prostate cancer in the ProtecT trial. Secondary analysis based on centralised biopsy review🔬 Article:
7
75
138
De escalated therapy is safe for stage IIA-IIB seminoma! ✅No recurrence since initial presentation in 2021. ✅No severe toxicity. ✅Secondary malignancies only outside of radiotherapy fields. Long term outcomes of SAKK 01/10 by @Alex_Papachris at #ESMO2
1
48
100
10 Years of experience with simulated trading. Turn your skills into rewards now!
0
10
8
STOPCAP at #ESMO26 Benefit of #radiotherapy in de novo M1 #prostatecancer on OS & PFS. Restricted to <5 bone or low volume mets on conventional imaging. No interaction with other patient/tumor characteristics.
3
53
112
Salvage brachytherapy for locally recurrent prostate cancer after definitive radiotherapy – a multicentric French cohort by the SFRO brachytherapy group https://t.co/Cx1PxgvyMB This large retrospective cohort study—the largest to date on salvage prostate brachytherapy
1
14
36
Proud to share our latest work on #prostatecancer reirradiation using #brachytherapy in @RO_GreenJournal
#openaccess link: https://t.co/eSwY1IT1VM in short: works well (iodine better), few significant tox in selected patients (worse with iodine)
3
13
62
Come join us in beautiful Melbourne!
5 weeks left to register for @PeterMacCC #SABR2025! Expert discussions, interactive sessions, fantastic faculty @PeterMacRadOnc
@PBlanchardMD
@lauren_henke
@BarbaraJereczek
@DrewMoghanaki
@Melissa_O_Neil This always sells out, register soon! https://t.co/O3ooI3ddky
0
2
13
Excellent summary/discussion on pelvic elective radiotherapy in #prostatecancer by @DrSpratticus as always.
As expected people resist letting go of dogma. Lets review the common examples people grasp at: 1. Nodal field size: cited as why GETUG01 was negative (S1/S2), then cited why RTOG 9413 was negative (L5/S1), then POP-RT positive (L4/L5), but definitive trial of RTOG 0924 (L4/L5)
0
2
8
Our @GETUG_Unicancer PEACE 2 trial will likely report at @ASCO #GU2026. Smaller than 0924 (761 pts) but higher risk patients, vast majority PET-staged (albeit choline). Planned number of events reached this summer. Stay tuned...
5
14
52
👨🎓 👩🎓 Les inscriptions au DU Radiothérapie des #cancers ORL de @GustaveRoussy et @UnivParisSaclay se déroulent jusqu'au 27 septembre. 🎓
1
1
2
This is THE best #prostatecancer meeting ever. Only occurs every other year. Strongly consider to submit your research and register. Lugano is a beautiful place and the content will be exceptional as usual.
🚨 Big News from #APCCC26 🚨 APCCC is opening a Call for Abstracts, creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer! Full details & submission 👉 https://t.co/LdNISUG3OK 📅 Key Dates: 🔹 Submission opens: 1 Sept
0
3
7